(Press-News.org) Results from a clinical trial of eteplirsen, a drug designed to treat Duchenne muscular dystrophy, suggest that the therapy allows participants to walk farther than people treated with placebo and dramatically increases production of a protein vital to muscle growth and health. The study, led by a team in The Research Institute at Nationwide Children's Hospital, is the first of its kind to show these results from an exon-skipping drug—a class of therapeutics that allows cells to skip over missing parts of the gene and produce protein naturally.
"I've been doing this for more than 40 years and this is one of the most exciting developments we've seen," says Jerry Mendell, MD, lead author of the study and director of the Center for Gene Therapy at Nationwide Children's. "It offers great hope to patients with Duchenne muscular dystrophy and their families."
The research, which appears online Aug. 1 in the journal Annals of Neurology, is the first study from a double-blind controlled randomized trial of an exon-skipping agent to provide conclusive proof based on the standard six-minute walk test used to measure muscle function in patients with Duchenne muscular dystrophy (DMD), the most common form of muscular dystrophy in children.
About one in every 5,000 male births in the U.S. has the disorder, which usually leaves patients unable to walk on their own by age 12. Children with DMD have a mutation that cripples the body's ability to produce a protein called dystrophin, which helps absorb the shock or energy that's created when a muscle contracts. Without it, that released energy injures muscle fibers. Over time, the muscle degenerates, scar tissue builds up and fat slowly replaces the dead muscle.
The exact mutation varies from patient to patient but in 65 percent of cases, the dystrophin gene is missing large sections of DNA called exons, which carry the instructions for protein production. Accompanying this type of mutation is a spontaneously occurring reaction that enables muscle cells to skip over the deleted sections and produce smaller—but functional—versions of protein.
Eteplirsen, manufactured by Sarepta Therapeutics in Cambridge, Mass., mimics this naturally occurring phenomenon, allowing cells to skip over exon 51 in the dystrophin gene. About 13 percent of patients with the disorder have this mutation. Nationwide Children's began the phase II trial of eteplirsen in August 2011, enrolling 12 boys age 7 to 12 years.
Participants received the drug via weekly IVs, with one group getting a 30 mg/kg dose and another group receiving 50 mg/kg. A control group received a placebo. Participants completed a six-minute walk test at the outset and again at weeks 12, 24 and 48. Muscle biopsies were also taken when the study began and again at those intervals to measure for dystrophin-positive muscle fibers.
Although there was no dystrophin production at 12 weeks, participants showed a 23 percent increase in dystrophin-positive muscle fibers by the 24-week mark. The striking improvement and lack of side effects prompted researchers to switch participants in the placebo group to the drug. By week 48, participants had a 52 percent increase in dystrophin-positive muscle fibers and were able to walk 67.3 meters farther than the placebo group on the six-minute walk test.
Although the results are promising, Dr. Mendell is quick to note that the small study leaves many questions unanswered. For example, researchers would like to know how the drug affects dystrophin production in muscles throughout the limbs and whether some muscles may get a bigger boost than others.
"We know that if you have an area that is not expressing dystrophin, the membrane will be fragile and vulnerable to activity-related degeneration," says Dr. Mendell, who also is director of the Neuromuscular Disorders program at Nationwide Children's and a professor of pediatrics in The Ohio State University College of Medicine. "There may be factors that lead to preferential localization of the dystrophin production. That's one of many issues we'd like to investigate further."
That information would help researchers determine what dose and frequency of administration would have the best benefit.
"Another big issue is whether patients who start to produce dystrophin will plateau quickly or if the drug would continue to show benefits over the long term," Dr. Mendell says.
Sarepta Therapeutics, which funded the study, plans to submit a New Drug Application to the Food and Drug Administration early next year. If approved, eteplirsen would be the first therapy for DMD to target the underlying cause of the disease.
INFORMATION: END
A Penn State-led research team has found that changes to proteins called histones, which are associated with DNA, can control whether or not a gene is allowed to function. The changes may be important in maintaining the genes' "expression potential" so that future cells behave as their parent cells did. The discovery, which may have implications for the study of diseases such as cancer, will be published in a print edition of the journal Proceedings of the National Academy of Sciences. The research was led by Lu Bai, an assistant professor of biochemistry, molecular biology, ...
Women living in large urban areas are at a significantly higher risk of postpartum depression after five to 14 months of giving birth compared to those living in rural areas, according to a new Canadian study led by Women's College Hospital's Dr. Simone Vigod.
The study, published today in the Canadian Medical Association Journal, strongly links geographic location and postpartum depression. The researchers suggest differences in risk factors, including place of birth, social support and history of depression, in combination with geography, may contribute to postpartum ...
Forests have a limited capacity to soak up atmospheric carbon dioxide, according to a new study from Northern Arizona University.
The study, available online in the journal New Phytologist, aimed to explore how rising atmospheric carbon dioxide could alter the carbon and nitrogen content of ecosystems.
By performing tests on subtropical woodland plots over an 11-year period, the researchers found that ecosystem carbon uptake was not significantly increased by the high CO2 treatment—in contrast to expectations. While plants did contain more carbon when CO2 levels were ...
The global study was led by University of Melbourne and the Peter MacCallum Cancer Centre and published in the Journal of Clinical Oncology today.
The study involved about 2,500 women from Europe, North America and Australia who have inherited mutations in BRCA1 or BRCA2, the breast cancer susceptibility genes, and who had been diagnosed with breast cancer. About one-third of these women were placed on tamoxifen.
Tamoxifen has been used for decades to treat breast cancer and has recently been shown to prevent breast cancers in many women.
Until now, there has been ...
RIVERSIDE, Calif. — Pregnant women regularly consume food and beverages containing toxins believed to pose potential risks to developing fetuses, according to researchers at the University of California in Riverside and San Diego, suggesting that health care providers must do more to counsel their patients about the dangers of hidden toxins in the food supply.
In a peer-reviewed study published in the July issue of Nutrition Journal — "Consumption habits of pregnant women and implications for developmental biology: a survey of predominantly Hispanic women in California" ...
Preliminary studies by Dr. Zhihong Chen and colleagues from Chengde Medical College have shown that sericin might improve aberrant Akt signaling, decrease heme oxygenase-1 expression in the hippocampus and cerebral cortex, and reduce the apoptosis of hippocampal neurons in diabetic rats, thus protecting the nervous system. Recently, it is reported that the growth hormone/insulin-like growth factor 1 axis undergoes abnormal changes in diabetes mellitus, which aggravate the disease progression and trigger complications. To improve diabetes mellitus and its chronic complications, ...
Breast cancer survivors who have extensive surgery are four times more likely to develop the debilitating disorder arm lymphoedema, a QUT study has found.
The findings in a new paper Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis published in the prestigious journal The Lancet Oncology, reveal the invasiveness of surgery to treat breast cancer increases the risk of developing arm lymphoedema.
Lead author of the study Tracey DiSipio, from QUT's Institute of Health and Biomedical Innovation, said women who had undergone ...
Griffith University researchers have taken part in an international study which has discovered a fast but accurate means of identifying changes to the biodiversity of a region.
And the secret lies in crushed up insect "soup".
Traditionally, many thousands of hours have been spent by researchers gathering, classifying and recording insects and animals in order to understand the natural ecology of a region. Any changes to the biodiversity of that area could then be determined only by more labour-intensive collecting and recording.
Research published today in the journal ...
(Santa Barbara, Calif.) –– Trying to explain riding a bike is difficult because it is an implicit memory. The body knows what to do, but thinking about the process can often interfere. So why is it that under certain circumstances paying full attention and trying hard can actually impede performance? A new UC Santa Barbara study, published today in the Journal of Neuroscience, reveals part of the answer.
There are two kinds of memory: implicit, a form of long-term memory not requiring conscious thought and expressed by means other than words; and explicit, another kind ...
Though one might think the brains of people who develop Alzheimer's disease (AD) possess building blocks of the disease absent in healthy brains, for most sufferers, this is not true. Every human brain contains the ingredients necessary to spark AD, but while an estimated 5 million Americans have AD – a number projected to triple by 2050 – the vast majority of people do not and will not develop the devastating neurological condition.
For researchers like Subhojit Roy, MD, PhD, associate professor in the Departments of Pathology and Neurosciences at the University of ...
